HC Wainwright Has Lowered Expectations for Korro Bio (NASDAQ:KRRO) Stock Price

Korro Bio (NASDAQ:KRRO) had its price target decreased by HC Wainwright from $115.00 to $100.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Korro Bio’s Q4 2026 earnings at ($2.17) EPS and FY2026 earnings at ($8.32) EPS.

A number of other equities analysts also recently weighed in on the stock. Chardan Capital assumed coverage on shares of Korro Bio in a research note on Wednesday, April 16th. They issued a “buy” rating and a $25.00 price target on the stock. Royal Bank of Canada cut their price target on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research note on Wednesday, March 19th. Oppenheimer assumed coverage on Korro Bio in a research note on Friday, January 10th. They issued an “outperform” rating and a $155.00 price target for the company. Finally, Cantor Fitzgerald raised shares of Korro Bio to a “strong-buy” rating in a research report on Tuesday, April 29th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $112.75.

Korro Bio Trading Up 1.0 %

Shares of KRRO stock opened at $15.56 on Thursday. The stock’s fifty day simple moving average is $17.78 and its 200-day simple moving average is $34.55. The company has a market capitalization of $146.12 million, a price-to-earnings ratio of -1.65 and a beta of 2.66. Korro Bio has a 1-year low of $11.13 and a 1-year high of $98.00.

Korro Bio (NASDAQ:KRRO) last issued its earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.60) by $0.11. The business had revenue of $2.55 million during the quarter, compared to analyst estimates of $0.13 million. On average, sell-side analysts predict that Korro Bio will post -9.52 EPS for the current year.

Institutional Trading of Korro Bio

Several large investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in shares of Korro Bio by 374.9% in the third quarter. JPMorgan Chase & Co. now owns 12,391 shares of the company’s stock valued at $414,000 after purchasing an additional 9,782 shares during the last quarter. Rhumbline Advisers grew its holdings in Korro Bio by 7.8% in the 4th quarter. Rhumbline Advisers now owns 9,602 shares of the company’s stock valued at $366,000 after buying an additional 691 shares during the last quarter. Bank of New York Mellon Corp increased its position in Korro Bio by 3.0% in the 4th quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company’s stock worth $563,000 after buying an additional 435 shares during the period. Raymond James Financial Inc. bought a new position in Korro Bio in the 4th quarter worth approximately $394,000. Finally, AlphaQuest LLC lifted its holdings in shares of Korro Bio by 23.2% during the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock worth $83,000 after buying an additional 412 shares during the last quarter. 13.18% of the stock is owned by institutional investors.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).